Dr Reddys Laboratories (RDY) Net Income towards Common Stockholders Growth (1y) (2010 - 2021)
Dr Reddys Laboratories (RDY) Net Income towards Common Stockholders Growth (1y) (2010 - 2021) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn | 68.18% |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn | -0.17% |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn | -388.62% |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn | -14.68% |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn | 105.80% |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn | 2,405.06% |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn | -14.93% |
| 10 | Dr Reddys Laboratories | 9.84 Bn | 9.68 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2021 | -10.07% |
| Mar 31, 2021 | -2.53% |
| Sep 30, 2020 | -35.00% |
| Jun 30, 2020 | -2.61% |
| Mar 31, 2020 | -15.96% |
| Sep 30, 2019 | -214.29% |
| Jun 30, 2019 | 121.74% |
| Mar 31, 2019 | 49.21% |
| Dec 31, 2018 | 43.18% |
| Sep 30, 2018 | 37.25% |
| Dec 31, 2017 | -8.33% |
| Sep 30, 2017 | -40.00% |
| Dec 31, 2016 | -38.46% |
| Sep 30, 2016 | -3.41% |
| Dec 31, 2015 | -6.02% |
| Sep 30, 2015 | -10.20% |
| Dec 31, 2014 | -12.63% |
| Sep 30, 2014 | -2.00% |
| Mar 31, 2014 | -99.26% |
| Dec 31, 2013 | -9.52% |